| AURINIA PHARMACEUT. |
| Kanada |
| Gesundheit |
| CA05156V1022 / A1W7D4 |
| IKAP (Frankfurt) / AUPH (NASDAQ) |
| FRA:IKAP, ETR:IKAP, IKAP:GR, NASDAQ:AUPH |
| - |
| https://www.auriniapharma.. |
|
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases that have high unmet medical needs. Its flagship product, LUPKYNIS..
>Volltext.. |
| 1668.17 Mio. EUR |
| 1392.81 Mio. EUR |
| 243.89 Mio. EUR |
| 116.79 Mio. EUR |
| 247.46 Mio. EUR |
| 1.87 EUR |
| 64.46 Mio. EUR |
| 69.11 Mio. EUR |
| 117.13 Mio. EUR |
| 4.25 |
| 6.1% |
| 4300.93% |
| - |
| - |
| - |
| AURINIA |
| 25.03.26 |
|